Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32361
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMargarit, César-
dc.contributor.authorBallester, Purificación-
dc.contributor.authorInda, María del Mar-
dc.contributor.authorRoca, Reyes-
dc.contributor.authorGomez, Luis-
dc.contributor.authorPlanelles, Beatriz-
dc.contributor.authorAjo Ferrer, Raquel-
dc.contributor.authorMorales, Domingo-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-06-27T11:29:27Z-
dc.date.available2024-06-27T11:29:27Z-
dc.date.created2019-01-
dc.identifier.citationPain Physician. 2019 Jan;22(1):97-107es_ES
dc.identifier.issn2150-1149-
dc.identifier.issn1533-3159-
dc.identifier.urihttps://hdl.handle.net/11000/32361-
dc.description.abstractBackground: The experience of chronic non-cancer pain (CNCP) is one of the most common reasons individuals seek medical attention. Patients with CNCP frequently experience concomitant sleep-related problems. Objectives: The aim was to evaluate sleep problems in opioid naïve CNCP patients, before and after opioid titration, analyzing the influence of OPRM1 gene variants. Study Design: A prospective, cohort, observational study. Setting: This study was performed at the Pain Unit of the Alicante University General Hospital. Methods: Pain and Medical Outcomes Study Sleep questionnaire (MOS-Sleep) were assessed at baseline and 3 months after opioid titration in 231 opioid naïve CNCP patients. Sleep data was compared with a matched-control group (n = 64). Morphine equivalent daily doses, adverse events, and drugs prescribed for pain were also registered. OPRM1 polymorphism rs1799971 was analyzed by RT-PCR. Ethics Committee approved the study and results were analyzed by R software. Results: After 3 months of opioid titration, patients with CNCP (63 ± 14 years, 64% female, VAS 74 ± 17 mm) significantly decreased pain intensity, anxiety and depression, and increased quality of life. Sleep problems were significantly more frequent in females (P = 0.002). Age, quality of life, anxiety, and depression all influenced sleep disturbances and problems indices, which were significantly different from the control group. Furthermore, the OPRM1 118- GG genotype was also associated with significantly lower sleep adequacy, and more sleep problems. Limitations: Total number of subjects studied was relatively small and most patients were on other non-opioid centrally-acting medications. Conclusions: Opioids decreased CNCP severity, improving patients’ psychological areas, and quality of life. However, patients with OPRM1 118-GG genotype indicated an increase in sleep problems and worsening sleep pattern while taking opioids.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent12es_ES
dc.language.isoenges_ES
dc.publisherPaducah, Ky. : American Society of Interventional Pain Physicianses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectOPRM1es_ES
dc.subjectpharmacogeneticses_ES
dc.subjectMOS-Sleepes_ES
dc.subjectopioidses_ES
dc.subjectchronic noncancer paines_ES
dc.subjectsleep related problemses_ES
dc.subjectsleep problem index SLP-6 and SLP-9es_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes_ES
dc.titleOPRM1 Gene Interaction with Sleep in Chronic Pain Patients Treated with Opioidses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
Appears in Collections:
Artículos Farmacología, Pediatría y Química Orgánica


Thumbnail

View/Open:
 OPRM1 Gene Interaction with Sleep in Chronic.pdf

207,46 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???